SUN PHARMACEUTICAL INDUSTRIES

BSE: 524715 12 Nov 2025

Healthcare

₹ 1636.15

Sun Pharmaceutical Industries Ltd. specializes in Pharmaceuticals within the Healthcare sector.

SUN PHARMACEUTICAL INDUSTRIES

BSE: 524715 12 Nov 2025

Healthcare

₹ 1636.15

Sun Pharmaceutical Industries Ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

301.0

Dividend Yield

1.01%

Debt to Equity

0.03

Stock P/E

33.2

Market Cap

3,80,702 Cr

SUN PHARMACEUTICAL INDUSTRIES - Share Price & Details

Market Cap

₹3,80,702

High /Low

1,960 / 1,547

Stock P/E

33.2

Book Value

₹301.0

Dividend Yield

1.01

ROCE

20.2

ROE

₹16.9

Face Value

1.0

PEG Ratio

1.65

EVEBITDA

₹20.8

Debt

2,362

CMP / FCF

45.9

Debt to equity

₹0.03

NP Ann

10,965

High price all time

1,960

Piotroski score

₹9.0

Graham Number

541.0

No. Eq. Shares

240.0

Net CF

₹983

Net profit

10,397

Price to book value

5.27

Interest Coverage

₹62.3

Low price all time

36.8

Industry PE

33.0

Reserves

₹71,978

Free Cash Flow

₹12,005

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
06 Nov 2025	Motilal Oswal	Buy	₹1,685.75	₹1,960	15.8%	moneycontrol	View
06 Nov 2025	Emkay Global Financial Services	Buy	₹1,685.75	₹2,000	17.7%	moneycontrol	View
05 Nov 2025	Prabhudas Lilladher	Buy	₹1,692.75	₹1,875	9.2%	moneycontrol	View
23 Sep 2025	Motilal Oswal	Buy	₹1,631.15	₹1,960	20.4%	moneycontrol	View
01 Aug 2025	Prabhudas Lilladher	Buy	₹1,629.05	₹1,875	14.2%	moneycontrol	View
31 Jul 2025	Motilal Oswal	Buy	₹1,705.55	₹1,960	19.3%	moneycontrol	View
28 May 2025	Deven Choksey	Buy	₹1,665.8	₹1,811	6.5%	moneycontrol	View
23 May 2025	Motilal Oswal	Buy	₹1,720	₹2,000	18.7%	moneycontrol	View
23 May 2025	Prabhudas Lilladher	Buy	₹1,720	₹2,000	18.7%	moneycontrol	View
10 Apr 2025	Emkay Global Financial Services	Buy	₹1,652.1	₹2,400	42.2%	moneycontrol	View
11 Mar 2025	ICICI Securities	Buy	₹1,611.15	₹1,895	14.4%	moneycontrol	View
04 Feb 2025	KRChoksey	Buy	₹1,767.05	₹1,967	11.4%	moneycontrol	View
01 Feb 2025	Prabhudas Lilladher	Buy	₹1,742.7	₹2,275	30.7%	moneycontrol	View
21 Jan 2025	Emkay Global Financial Services	Buy	₹1,775.9	₹2,400	36.1%	moneycontrol	View
30 Oct 2024	KRChoksey	Buy	₹1,852.45	₹1,967	8.8%	moneycontrol	View
29 Oct 2024	Prabhudas Lilladher	Buy	₹1,870.9	₹2,100	16.2%	moneycontrol	View
28 Oct 2024	Sharekhan	Buy	₹1,902.65	₹2,264	25.3%	moneycontrol	View
13 Aug 2024	KRChoksey	Buy	₹1,739.75	₹1,827	1.1%	moneycontrol	View
01 Aug 2024	Motilal Oswal	Buy	₹1,715.95	₹1,980	9.9%	moneycontrol	View
01 Aug 2024	Prabhudas Lilladher	Buy	₹1,715.95	₹1,885	4.7%	moneycontrol	View
23 May 2024	ICICI Securities	Hold	₹1,494.95	₹1,463	-18.7%	moneycontrol	View
23 May 2024	Prabhudas Lilladher	Buy	₹1,494.95	₹1,710	-5%	moneycontrol	View
23 May 2024	KRChoksey	Buy	₹1,494.95	₹1,827	1.4%	moneycontrol	View
22 May 2024	Motilal Oswal	—	₹1,540.3	₹1,810	0.5%	moneycontrol	View
24 Apr 2024	Motilal Oswal	Buy	₹1,486.35	₹1,870	3.8%	moneycontrol	View
19 Mar 2024	Emkay Global Financial Services	Buy	₹1,551.15	₹1,827	1.4%	moneycontrol	View
11 Mar 2024	Sharekhan	Buy	₹1,592.4	₹1,727	-4%	moneycontrol	View
01 Feb 2024	Prabhudas Lilladher	Buy	₹1,406.55	₹1,640	-8.8%	moneycontrol	View
31 Jan 2024	Motilal Oswal	Buy	₹1,418.5	₹1,635	-9.1%	moneycontrol	View
31 Jan 2024	ICICI Securities	Hold	₹1,418.5	₹1,400	-22.2%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	2.21	-0.31	NA	-1.25	0
SUN PHARMACEUTICAL INDUSTRIES	46209.0	5642.2	45481.1	2.4	3,80,702	33.2
DIVIS LABORATORIES LTD.	28060.0	6960.0	26600.0	26.24	151038	65.5
CIPLA LTD.	78583.9	13533.7	75894.4	16.72	121115	22.5

Peer Comparison Chart

About SUN PHARMACEUTICAL INDUSTRIES

Sun Pharmaceutical Industries Ltd., with Security Code 524715, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Collective Mining Ltd Stock Analysis and Forecast - MACD Trading Signals & Market Volatility Strategies

(27 Sep 2025)

【Market Sentiment】✌️ Analyze market trends like a pro with our real-time financial tools.

Sun Pharma faces US tariff uncertainty; analysts see limited earnings risk

(27 Sep 2025)

Nearly $1.1 billion in the company's US revenue comes from patented and specialty drugs, which are potentially exposed to the new tariffs.

Sun Pharma Share Price: Stock drops over 4% post Trump's tariffs on branded drugs, Nifty pharma falls over 2%

(26 Sep 2025)

Sun Pharma Share Price: Shares of Sun Pharmaceutical Industries Ltd fell nearly 5 per cent to a new 52-week low of Rs 1547.25 on the BSE.

Sun Pharma Leads Pharma Stocks Decline After Trump Hikes Tariff To 100%

(26 Sep 2025)

Sun Pharmaceutical Industries Ltd. declined nearly 5% on Friday as Trump announced 100% tariff on the Pharmaceutical sector unless the...

HSBC says only Sun Pharma exposed to 100% U.S. tariffs; limited impact on earnings expected

(26 Sep 2025)

Patented products amount to 17% of Sun Pharma's total revenue and 8-10% of consolidated EPS in FY25.

India’s pharma sees limited risk as US slaps 100% tariff on branded and patented drug imports

(26 Sep 2025)

The move holds significance for India, the single largest exporter of pharmaceuticals to the US, with shipments worth $7.1 billion in FY24.

Quarterly Table

Standalone Consolidated

Metrics	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025	Sep 2025
Sales	4,548.1	4,548.1	4,548.1	4,548.1	4,548.1	4,548.1	4,548.1	4,548.1	4,548.1	4,548.1
Expenses	3,364.5	3,364.5	3,364.5	3,364.5	3,364.5	3,364.5	3,364.5	3,364.5	3,364.5	3,364.5
Operating Profit	1,183.6	1,183.6	1,183.6	1,183.6	1,183.6	1,183.6	1,183.6	1,183.6	1,183.6	1,183.6
OPM %	26.02%	26.02%	26.02%	26.02%	26.02%	26.02%	26.02%	26.02%	26.02%	26.02%
Other Income	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8	72.8
Interest	248.3	248.3	248.3	248.3	248.3	248.3	248.3	248.3	248.3	248.3
Depreciation	336.3	336.3	336.3	336.3	336.3	336.3	336.3	336.3	336.3	336.3
Profit before tax	671.8	671.8	671.8	671.8	671.8	671.8	671.8	671.8	671.8	671.8
Tax %	16%	16%	16%	16%	16%	16%	16%	16%	16%	16%
Net Profit	564.2	564.2	564.2	564.2	564.2	564.2	564.2	564.2	564.2	564.2
EPS in Rs	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4	2.4

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Sep 2025
Sales	10,930.7	11,940.8	12,192.4	12,380.7	11,982.9	12,652.8	13,291.4	13,675.5	12,958.8	14,478.3
Expenses	8,162.4	8,616.5	9,028.7	8,911.4	8,955.6	9,055.9	9,352.4	9,671.0	9,249.4	9,963.4
Operating Profit	2,768.3	3,324.4	3,163.7	3,469.3	3,027.3	3,596.9	3,939.0	4,004.5	3,709.5	4,514.9
OPM %	25.33%	27.84%	25.95%	28.02%	25.26%	28.43%	29.64%	29.28%	28.62%	31.18%
Other Income	201.8	-118.4	293.6	180.4	504.3	532.6	354.0	149.5	251.2	469.9
Interest	92.7	80.9	49.3	34.7	73.6	61.5	69.2	51.5	49.1	99.9
Depreciation	671.5	651.3	632.8	622.1	650.4	655.1	625.9	630.6	663.8	729.5
Profit before tax	2,377.3	2,796.6	2,775.2	3,062.7	2,909.3	3,412.8	3,597.9	3,788.0	3,609.4	4,155.5
Tax %	-10%	-18.9%	-14%	-14.4%	-5.3%	-16.1%	-15.8%	-16.1%	-33.6%	-24.7%
Net Profit	1,982.9	2,005.7	2,385.1	2,560.5	2,658.7	2,860.5	3,037.3	2,913.0	2,153.9	3,125.0
EPS in Rs	8.3	8.4	9.9	10.5	11.1	11.8	12.7	12.1	0	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	11%
5 Years:	13%
3 Years:	14%
TTM:	13%

Compounded Profit Growth
10 Years:	17%
5 Years:	7%
3 Years:	73%
TTM:	40%

Stock Price CAGR
10 Years:	6%
5 Years:	30%
3 Years:	24%
1 Year:	15%

Compounded Sales Growth
10 Years:	7%
5 Years:	10%
3 Years:	11%
TTM:	8%

Compounded Profit Growth
10 Years:	10%
5 Years:	24%
3 Years:	20%
TTM:	15%

Stock Price CAGR
10 Years:	6%
5 Years:	30%
3 Years:	24%
1 Year:	15%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

SUN PHARMACEUTICAL INDUSTRIES

SUN PHARMACEUTICAL INDUSTRIES

SUN PHARMACEUTICAL INDUSTRIES - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About SUN PHARMACEUTICAL INDUSTRIES

Order Book

Latest News

Collective Mining Ltd Stock Analysis and Forecast - MACD Trading Signals & Market Volatility Strategies

Sun Pharma faces US tariff uncertainty; analysts see limited earnings risk

Sun Pharma Share Price: Stock drops over 4% post Trump's tariffs on branded drugs, Nifty pharma falls over 2%

Sun Pharma Leads Pharma Stocks Decline After Trump Hikes Tariff To 100%

HSBC says only Sun Pharma exposed to 100% U.S. tariffs; limited impact on earnings expected

India’s pharma sees limited risk as US slaps 100% tariff on branded and patented drug imports

Decline in pharma stocks today due to Trump tariff is largely ‘sentimental’ | Business News

Stock Picks Today: Infosys, Sun Pharma, Swiggy, Adani Ports, IndusInd Bank On Brokerages Radar

Leuprolide Acetate Market Outlook to Witness Massive Growth

Sun Pharma’s Sonidegib Study Completion: A Boost for Oncology Market Presence

Threat of US tariffs hangs over Sun Pharma’s specialty business | Stock Market News

Sun Pharma has shuffled its top deck. The bet is on. | Company Business News

Pharma stock to buy now for an upside of 35%; Recommended by Citi

NSE/BSE, Top Gainers & Top Losers Today 18 September 2025: Eternal, Sun Pharma, Infosys, HDFC Bank, HCLTech

Sun Pharmaceutical Industries Ltd up for third straight session

Sun Pharma added to Citi's pan-Asia focus list with 35% upside

Citi names this pharma stock top pick on pan-Asia focus list, sees strong upside

ITC, Sun Pharmaceutical and 3 other fundamentally strong stocks trading below 200 DMA

Sun Pharmaceutical Industries (NSE:SUNPHARMA) shareholders have earned a 27% CAGR over the last five years

Sun Pharmaceutical Industries (NSEI:SUNPHARMA) - Stock Analysis

US FDA Flags Sun Pharma’s Halol Plant with ‘Official Action Indicated’ Status amid Repeat Safety Breaches

Sun Pharmaceutical Industries Ltd up for third consecutive session

Sun Pharmaceutical Industries rises Thursday, outperforms competitors

Sun Pharma: What JM Financial says as Halol plant gets OAI tag; check key stock drivers

Sensex, Nifty set for a positive start; Kotak Bank, Tata Motors, Vodafone Idea, Sun Pharma shares in focus

Sun Pharmaceutical Industries falls Wednesday, underperforms competitors

Sun Pharma’s Halol plant under US FDA import alert, shipments halted

US FDA deems Sun Pharma's Halol plant not compliant with its manufacturing rules

Sun Pharma Shares Slump as USFDA Indicates OAI Status

Sensex, Nifty set for a positive start; Kotak Mahindra Bank, Tata Motors, Vodafone Idea, Sun Pharma shares in focus

Infosys, Sun Pharma, Strides Pharma, Railtel, Vedanta, Tata Communications, Ujjivan SFB, IRB Infra to draw market attention on Tuesday (September 9, 2025)

Sun Pharmaceutical Industries slides Monday, underperforms competitors

Sun Pharma, Lupin push for affordable anti-obesity pills in India - Mint

Sun Pharma discontinues manufacturing of vecuronium bromide injection 20 mg, says FDA

Now Sun Pharma, Lupin work on anti-obesity pill to cut costs, address jab aversion | Company Business News

From ‘maybe’ to ‘must do’: Sun Pharma’s diabetes pitch

Generic Drugs Market is expected to reach US$ 942.69 billion

SUNPHARMA Outlook for the Week

Sun Pharma launches digital campaign for Prohance D Diabetes Care with ‘Dekhta Hoon Nahi, Dikhata Hoon’

Sun Pharma stock slips 2% in firm market, nears 52-week low; here's why

Top Gainers and Losers Today, 27 August 2025: Eicher Motors Ltd, Hindustan Unilever Ltd lead gains; Shriram Finance Ltd, Sun Pharmaceutical Industries Ltd among top losers

Will Weakness in Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Stock Prove Temporary Given Strong Fundamentals?

Sun Pharma, Lupin, Dr Reddy’s Drop Up To 4% As Trump’s Pharma Shock Spooks Investors

Pharma stocks take a hit as Trump issues fresh warning; key details

Sensex, Nifty fall up to 0.7% on U.S. tariff fears; realty, pharma lead losses

Sun Pharma target cut: BofA flags risks to consensus earnings, rich valuations

Sun Pharma drops as foreign broker downgrades on valuation, execution risks

Saudi Arabia Generic Drugs Market Outlook and Company Analysis 2025-2033 Featuring Teva, Viatris, Sa

Sun Pharmaceutical Industries climbs Wednesday, outperforms competitors

Sun Pharma Asks Judge to Freeze Nivagen Suit Pending Transfer

Sun Pharmaceutical Industries Ltd gains for third consecutive session

Sun Pharma’s Volini Launches Innovative ‘Uparna’ for Pandharpur Pilgrims

(PDF) FINANCIAL PERFORMANCE ANALYSIS OF SUN PHARMACEUTICAL INDUSTRIES LTD., IN LAST FIVE YEARS

Sun Pharma Adv Consolidated June 2025 Net Sales at Rs 9.64 crore, down 42.65% Y-o-Y

Burn Pain Market: Epidemiology, Therapies, Companies, DelveInsight | Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, Trio Li

Sun Pharma’s Volini launches pain relief innovation for Warkaris with culturally inspired ‘Volini Uparna’

7 Stocks To Buy For Long Term: Analysts recommend largecap, midcap scrips; Sun Pharma, UltraTech on the list

Earnings Miss: Sun Pharmaceutical Industries Limited Missed EPS By 22% And Analysts Are Revising Their Forecasts

Sun Pharma shares fall 5.7% post Q1 results: What should investors do now?

Sun Pharma Gets Relief As Delhi HC Bars Use of BERIVITAL, BEZOLIC, DOZE-30 For Trademark Infringement

Sun Pharmaceutical Industries Limited (524715) Stock Experiences Sudden Dip - Invest confidently with professional market insights

Transcript : Sun Pharmaceutical Industries Limited, Q1 2026 Earnings Call, Jul 31, 2025

Sun Pharma FY25 Results: Rs 54,543 Cr Revenue, Rs 12,000 Cr Profit Milestone

Sun Pharmaceutical says it won't expand US manufacturing base amid tariff concerns

Sun Pharma Q1 Preview: Earnings likely to rise on India, specialty strength; margin impact from new...

Sun Pharmaceutical Q1 Results: Profit Falls 20% As Exceptional Loss Weighs

Sun Pharma Rises 2.65% on US Launch of Alopecia Drug LEQSELVI

Sun Pharma Shares Decline Over 5% As Q1 Profit Falls 20%

Sun Pharma Shares Slide 5% After Q1 Profit Drops 20%; Should You Buy, Hold or Sell? Check Brokerages' Ratings